Streetbeat News

Products Services

DATS

DatChat (NASDAQ:DATS), a secure messaging, social media, and metaverse company, has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application titled 'Technology platform for providing secure group-based access to sets of digital assets.' The patent will protect the core technology that will power DatChat's secure personal and enterprise data archive platform, expected to launch in early 2024.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:34 pm

GPAK

Gamer Pakistan is developing a next-generation 5G Edge mobile gaming platform. The platform will be launched in phases, starting with a mobile streaming platform. The final platform will include 4K streaming technology and Edge AI technology to enhance esports. The AI tools will provide player performance analysis, real-time in-app gameplay analytics, immersive experiences for players, content creation, audience engagement, esports betting, broadcasting, sponsorship and marketing, and game development.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:33 pm

ICU

SeaStar Medical Holding Corporation (NASDAQ:ICU) has received the U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its Selective Cytopheretic Device (SCD) for use with patients with acute kidney injury and acute on chronic liver failure. This is the third such designation granted to SeaStar for the SCD device, which is expected to expedite its clinical development and regulatory review. The SCD has shown potential in improving solid organ function in various conditions, including sepsis, AKI, cardiorenal syndrome, and COVID-19.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:33 pm

GENE

Genetic Technologies Limited (NASDAQ:GENE) has announced the publication of a peer-reviewed research paper validating geneType's Pancreatic Cancer risk assessment test. The test showed a nearly 50% improvement to the traditional clinical risk score in identifying patients at a high risk of developing pancreatic cancer. The study evaluated close to 380,000 adults aged 40 to 69 years from the UK Biobank.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:33 pm

IMNN

IMUNON, Inc. (NASDAQ:IMNN) has announced the enrollment of the first patient in a Phase 1/2 clinical trial evaluating IMNN-001 in combination with bevacizumab for advanced ovarian cancer. The trial aims to enroll 50 patients with Stage III/IV advanced ovarian cancer. Initial data are expected within one year following the completion of enrollment and final data are expected approximately three years after. The company has recently announced encouraging interim data for their OVATION 2 program evaluating the benefits of IMNN-001.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:32 pm

BNMV

BitNile Metaverse, Inc. (NASDAQ:BNMV) announced the addition of Over-Under Dice to its online metaverse platform, BitNile.com. The game is expected to launch on October 31, 2023, and will complement the platform's existing range of social gaming. The platform is browser-based and does not require a specialized headset. The company also plans to add video poker and bingo later this year.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:31 pm

TKLF

Japanese retailer Yoshitsu Co., Ltd (NASDAQ:TKLF) has announced plans to launch direct-sale stores in Canada. The company aims to streamline its operational processes, improve its responsiveness to customer preferences, and enhance its brand awareness in the Canadian market. The stores will offer a comprehensive range of products, including beauty essentials, health commodities, sundry products, and other products such as food and alcoholic beverages.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:21 pm

ENSC

Ensysce Biosciences (NASDAQ:ENSC) announced that Dr. Dolly Jacob from Quotient Sciences will present their collaborative work on an extended release nafamostat formulation for prescription drug overdose protection at the AAPS 2023 PharmSci 360 event. The presentation will feature the development of Ensysce's PF614-MPAR for severe pain treatment, designed to prevent abuse and overdose.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:20 pm

GOOG

GOOGL

META

MSFT

A study by researchers at ETH Zurich has found that AI chatbots, such as Microsoft's OpenAI's ChatGPT, can accurately guess personal information like age, gender, location, and job based on what users type. The study used over 500 Reddit user-profiles and posts from 2012 to 2016 for analysis. OpenAI's GPT-4 was found to be the most accurate, with an accuracy rate of 84.6%, compared to Meta Platforms' Llama 2, Alphabet's Google PaLM, and Anthropic's Claude.

Portfolio Pulse from Rounak Jain

October 18, 2023 | 12:17 pm

NICE

Mazda Motor Europe has transitioned its on-premise customer experience (CX) operations to a unified cloud platform with CXone, an AI-powered solution provided by NICE Ltd.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 12:15 pm